{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T19:12:49Z","timestamp":1762542769579,"version":"3.37.3"},"reference-count":9,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Harm Reduct J"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s12954-017-0201-y","type":"journal-article","created":{"date-parts":[[2017,11,24]],"date-time":"2017-11-24T22:41:38Z","timestamp":1511563298000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Why is there still hepatitis C transmission in Australian prisons? A case report"],"prefix":"10.1186","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6709-4636","authenticated-orcid":false,"given":"Ben","family":"Harkness","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Levy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruth","family":"Evans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jillian","family":"Wenke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,11,25]]},"reference":[{"issue":"S2","key":"201_CR1","doi-asserted-by":"crossref","first-page":"S105","DOI":"10.1093\/cid\/cit301","volume":"57","author":"B Grady","year":"2013","unstructured":"Grady B, Schinkel J, Thomas X, Dalgard O. Hepatitis C virus reinfection following treatment among people who use drugs. Clin Infect Dis. 2013;57(S2):S105\u201310.","journal-title":"Clin Infect Dis"},{"key":"201_CR2","unstructured":"Fourth National Hepatitis C Strategy 2014\u20132017. Australian Government. Canberra 2014 (Accessed 30 May 2017)\nhttp:\/\/www.health.gov.au\/internet\/main\/publishing.nsf\/content\/A68444CDED77B3A9CA257BF0001CFD80\/$File\/Hep-C-Strategy2014-v3.pdf"},{"issue":"1","key":"201_CR3","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jhep.2016.02.007","volume":"65","author":"N Martin","year":"2016","unstructured":"Martin N, Vickerman P, Dore G, Grebely J, Miners A, Cairns J, Foster G, Hutchinson S, Goldberg D, Martin T, Ramsay M, Hickman M. Prioritization of HCV treatment in the direct-acting antiviral era: an economic evaluation. J Hepatol. 2016;65(1):17\u201325.","journal-title":"J Hepatol"},{"key":"201_CR4","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/j.drugpo.2015.07.005","volume":"26","author":"J Grebely","year":"2015","unstructured":"Grebely J, Robaeys G, Bruggmann P, Aghemo A, Backmund M, Bruneau J, Byrne J, Dalgard O, Feld J, Hellard M, Hickman M, Kautz A, Litwin A, Lloyd A, Mauss S, Prins M, Swan T, Schaefer M, Taylor L, Dore G. Recommendations for the management of hepatitis C virus infection among people who inject drugs. Int J Drug Policy. 2015;26:1028\u201338.","journal-title":"Int J Drug Policy"},{"issue":"5","key":"201_CR5","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1002\/hep.28609","volume":"64","author":"A Foschi","year":"2016","unstructured":"Foschi A, Casana M, Radice A, Ranieri R, Monforte A. Hepatitis C management in prisons: an insight into daily clinical practice in three major Italian correctional houses. Hepatology. 2016;64(5):1821\u20132.","journal-title":"Hepatology"},{"key":"201_CR6","unstructured":"Australian Medical Association. Hepatitis C Cure Could Come At A Cost. Australian Medicine (\/ausmed) March 15, 2016. \nhttps:\/\/ama.com.au\/ausmed\/hepatitis-c-cure-could-come-cost\n\n (Accessed 20\/06\/2017)."},{"issue":"10","key":"201_CR7","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1377\/hlthaff.2016.0296","volume":"35","author":"A Beckman","year":"2016","unstructured":"Beckman A, Bilinski A, Boyko R, Camp G, Wall A, Lim J, Wang E, Bruce R, Gonsalves G. New hepatitis C drugs are very costly and unavailable to many state prisoners. Health Aff. 2016;35(10):1893\u2013901.","journal-title":"Health Aff"},{"key":"201_CR8","doi-asserted-by":"crossref","first-page":"e5615","DOI":"10.1136\/bmj.e5615","volume":"345","author":"M Sweet","year":"2012","unstructured":"Sweet M. Needle and syringe exchange programme is announced for Australian prison. Br Med J. 2012;345:e5615. (published 17 August 2012)","journal-title":"Br Med J"},{"issue":"6","key":"201_CR9","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1093\/cid\/civ948","volume":"62","author":"B Simmons","year":"2016","unstructured":"Simmons B, Saleem J, Hill A, Riley R, Cooke G. Risk of late relapse or reinfection with hepatitis C virus after achieving a sustained virological response: a systematic review and meta-analysis. Clin Infect Dis. 2016;62(6):683\u20139.","journal-title":"Clin Infect Dis"}],"container-title":["Harm Reduction Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-017-0201-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,11,24]],"date-time":"2017-11-24T22:41:52Z","timestamp":1511563312000},"score":1,"resource":{"primary":{"URL":"https:\/\/harmreductionjournal.biomedcentral.com\/articles\/10.1186\/s12954-017-0201-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,25]]},"references-count":9,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["201"],"URL":"https:\/\/doi.org\/10.1186\/s12954-017-0201-y","relation":{},"ISSN":["1477-7517"],"issn-type":[{"type":"electronic","value":"1477-7517"}],"subject":[],"published":{"date-parts":[[2017,11,25]]},"article-number":"75"}}